Prostate-specific antigen cancer volume: A significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 38, Issue 2, 1997, Pages 327-333

  Lankford, Scott P ^a   Pollack, Alan ^a,b   Zagars, Gunar K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Box 97 ^*  (United States)

Author keywords

Prognostic factors; Prostate cancer; PSA cancer volume; PSA density; Radiotherapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RISK ASSESSMENT; TREATMENT FAILURE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030755526     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00627-X     Document Type: Article

References (24)

1. Aihara, M.; Lebovitz, R. M.; Wheeler, T. M.; Kinner, B. M.; Ohori, M.; Scardino, P. T. Prostate specific antigen and gleason grade: An immunohistochemical study of prostate cancer. J. Urol. 151:1558-1564; 1994.
2. Altman, D. G. Practical statistics for medical research. London: Chapman and Hall; 1991:179-268.
3. American Joint Committee on Cancer. Manual for staging cancer, 4th ed. Beahrs, O. H.; Henson, D. E.; Hutter, R. V. P.; Kennedy, B. J., eds. Philadelphia: J. P. Lippincott; 1992:181-183,
4. Blackwell, K. L.; Bostwick, D. G.; Myers, R. P.; Zinke, H.; Oesterling, J. E. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: The influence of prostate specific antigen cancer density. J. Urol. 151:1565-1570; 1994.
5. Carlton, J. C.; Zagars, G. K.; Oswald, M. J. The role of serum prostatic acid phosphatase in the management of adenocarcinoma of the prostate with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 19:1383-1388; 1990.
6. Corn, B. W.; Hanks, G. E.; Lee, W. R.; Bonin, S. R.; Hudes, G.; Schultheiss, T. Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. J. Urol. 153:1855-1859; 1995.
7. D'Amico, A. V.; Propert, K. J. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (in press).
8. Harris, E. K.; Albert, A. Survivorship analysis for clinical studies. New York: Marcel Dekker; 1991:5-125.
9. Lee, W. R.; Hanks, G. E.; Schultheiss, T. E.; Corn, B. W.; Hunt, M. A. Localized prostate cancer treated by externalbeam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol. 13:464-469; 1995.
10. Lepor, H.; Wang, B.; Shapiro, E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 44:199-205; 1994.
11. Marks, L. S.; Treiger, B.; Dorey, F. J.; Fu, Y. S.; deKernion, J. B. Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology 44:486-492; 1994.
12. McNeal, J. E. Cancer volume and site of origin of adenocarcinoma of the prostate: Relationship to local and distant spread. Hum. Pathol. 23:258-266; 1992.
13. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, E. D.; Kozelsky, T. F.; Wieand, H. S.; Oesterling, J. E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2166; 1993.
14. Pollack, A.; Lankford, S.; Zagars, G. K.; Babaian, R. J. PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy. Cancer 77:1515-1523; 1996.
15. Pollack, A.; Zagars, G. K.; Kopplin, S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:13-20; 1995.
16. Pollack, A.; Zagars, G. K.; Starkschall, G.; Childress, C. H.; Kopplin, S.; Boyer, A. L.; Rosen, I. I. Conventional versus conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int. J. Radiat. Oncol. Biol. Phys. 34:555-564; 1996.
17. Stamey, T. A.; Freiha, F. S.; McNeal, J. E.; Redwine, E. A.; Wittemore, A. S.; Schmid, H.-P. Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933-938; 1993.
18. Steel, R. G. D.; Torrie, J. H. Principles and procedures of statistics: A biometrical approach. New York: McGraw-Hill; 1980.
19. Zagars, G. K.; Geara, F. B.; Pollack, A.; von Eschenbach, A. C. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer 74:1904-1912; 1994.
20. Zagars, G. K.; Pollack, A.; Kavadi, V. S.; von Eschenbach, A. C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-306; 1995.
21. Zagars, G. K.; Pollack, A.; von Eschenbach, A. C. Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen. Int. J. Radiat. Oncol. Biol. Phys. 33:23-35; 1995.
22. Zagars, G. K.; von Eschenbach, A. C.; Johnson, D. E.; Oswald, M. J. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60:1489-1499; 1987.
23. Zeitman, A. L.; Coen, J. J.; Shipley, W. U.; Willett, C. G.; Efird, J. T. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 151:640-645; 1994.
24. Zentner, P. G.; Pao, L. K.; Benson, M. C.; McMahahon, D. J.; Schiff, P. B. Prostate-specific antigen density: A new prognostic indicator for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 27:47-58; 1993.